Therapeutic effects of micheliolide on a murine model of rheumatoid arthritis

  • Authors:
    • Hua Xu
    • Jian Wang
    • Chijuan Wang
    • Guoqiang Chang
    • Yani Lin
    • Hongju Zhang
    • Hairui Zhang
    • Qinghua Li
    • Tianxiang Pang
  • View Affiliations

  • Published online on: October 24, 2014     https://doi.org/10.3892/mmr.2014.2767
  • Pages: 489-493
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Rheumatoid arthritis (RA) is a systemic autoimmune disease and collagen‑induced arthritis (CIA) is an animal model for RA. Micheliolide (MCL) is a novel compound with strong anti‑inflammatory effects. The present study was conducted to evaluate the therapeutic effects of MCL on RA. Mice were randomly divided into four groups and the CIA model mice were treated with methotrexate (MTX), MCL and dimethyl sulfoxide. A score associated with the severity of arthritis was assigned on alternate days from the 22nd day for 60 days. Histopathological changes and the serum levels of cytokines were measured on day 85. The results demonstrated that the MCL treatment group had arthritis scores lower than the CIA group and higher than the MTX group; compared with the CIA group, MCL and MTX significantly reduced the swelling of the paws and suppressed the degeneration of articular cartilage. Expression levels of macrophage colony‑stimulating factor (M‑CSF), tissue inhibitors of metalloproteinases‑1 (TIMP‑1) and complement component 5a (C5/C5a) were lower in the mice with arthritis compared with normal mice, however, following treatment with MCL and MTX, all the mice exhibited significant recovery to differing degrees. Unlike the MTX group, the MCL group failed to recover the level of soluble intercellular adhesion molecule‑1. In addition, the cytokine of B‑lymphocyte chemoattractant (BLC) solely presented in the MCL group. These results suggest that MCL may be considered for use as a novel therapeutic treatment against RA and that changes in the expression of cytokines C5/C5a, TIMP‑1, M‑CSF and BLC may underlie the mechanism by which MCL effects changes in this disease.
View Figures
View References

Related Articles

Journal Cover

January-2015
Volume 11 Issue 1

Print ISSN: 1791-2997
Online ISSN:1791-3004

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Xu H, Wang J, Wang C, Chang G, Lin Y, Zhang H, Zhang H, Li Q and Pang T: Therapeutic effects of micheliolide on a murine model of rheumatoid arthritis. Mol Med Rep 11: 489-493, 2015
APA
Xu, H., Wang, J., Wang, C., Chang, G., Lin, Y., Zhang, H. ... Pang, T. (2015). Therapeutic effects of micheliolide on a murine model of rheumatoid arthritis. Molecular Medicine Reports, 11, 489-493. https://doi.org/10.3892/mmr.2014.2767
MLA
Xu, H., Wang, J., Wang, C., Chang, G., Lin, Y., Zhang, H., Zhang, H., Li, Q., Pang, T."Therapeutic effects of micheliolide on a murine model of rheumatoid arthritis". Molecular Medicine Reports 11.1 (2015): 489-493.
Chicago
Xu, H., Wang, J., Wang, C., Chang, G., Lin, Y., Zhang, H., Zhang, H., Li, Q., Pang, T."Therapeutic effects of micheliolide on a murine model of rheumatoid arthritis". Molecular Medicine Reports 11, no. 1 (2015): 489-493. https://doi.org/10.3892/mmr.2014.2767